Trump Administration Moves to Expand Federal Support for Psychedelic Medicines

On April 18, 2026, President Donald Trump signed an executive order titled "Accelerating Medical Treatments for Serious Mental Illness," directing multiple federal agencies to clear regulatory barriers for psychedelic drugs including psilocybin, MDMA, ibogaine, and LSD [1]. The order commits $50 million in ARPA-H funding to match state investments in psychedelic research, creates National Priority Vouchers enabling FDA review in potentially "just weeks" according to FDA Commissioner Mary Makary, and opens a Right to Try pathway for patients to access investigational psychedelic compounds [2].

The order represents the most aggressive federal action on psychedelic medicine in U.S. history. But behind the bipartisan applause from veterans' advocates and the stock surges among biotech firms lies a more complicated picture — one involving an FDA rejection still reverberating through the field, unresolved safety concerns, equity gaps in clinical research, and a fundamental disagreement about whether government-backed medicalization is the right path forward.

The Executive Order and What It Actually Does

The executive order directs the FDA, DEA, VA, HHS, and private sector to coordinate on increasing clinical trial participation and establishing patient access pathways [1]. Three companies have already received National Priority Vouchers: two studying psilocybin for treatment-resistant depression and one studying methylone, an MDMA-related compound, for PTSD [3].

The order also invokes the Right to Try Act, signed in 2018, to allow eligible patients access to investigational psychedelic drugs that have met basic safety requirements but are not yet FDA-approved [2]. In 2025, the administration signed the HALT Fentanyl Act, which reformed the process for conducting medical research on Schedule I substances, removing a significant bureaucratic barrier to psychedelic research [3].

Compared to the Biden administration's approach — which centered on FDA Breakthrough Therapy designations and allowed the agency's standard review process to play out, including its August 2024 rejection of MDMA therapy — the Trump order represents a direct intervention in the regulatory timeline [4]. Harvard Law professors I. Glenn Cohen and Mason Marks noted the order raises questions about the appropriate boundary between executive action and independent scientific review [5].

Veterans at the Center

The political case for psychedelic therapy runs through the Department of Veterans Affairs. The VA awarded approximately $1.5 million over five years for MDMA-assisted therapy research at Brown University and Yale University, with studies at the Providence and West Haven VA Medical Centers [6]. Nine VA facilities now participate in expanded psychedelic trials across the country, studying PTSD, treatment-resistant depression, anxiety disorders, and alcohol use disorder [7].

Source: VA News / Military.com

Data as of Apr 25, 2026CSV

The Innovative Therapies Centers of Excellence Act of 2025, introduced by Reps. Lou Correa (D-CA) and Jack Bergman (R-MI) — co-chairs of the bipartisan Psychedelics Advancing Therapies (PATH) Caucus — and sponsored in the Senate by Sen. Ruben Gallego (D-AZ), would designate at least five VA medical facilities to offer psychedelic therapeutic modalities and appropriate $30 million per fiscal year for research and education [8]. A companion bill, the Veterans Health Administration Novel Therapeutics Preparedness Act, would build internal VA infrastructure to deploy psychedelic therapies once FDA-approved [9].

But current federal funding for psychedelic research remains modest compared to the VA's broader mental health spending. The $1.5 million allocated for the first MDMA study contrasts with billions spent annually on traditional pharmacological treatments for PTSD and depression across the VA system [6]. The $50 million ARPA-H commitment is contingent on matching state investments, and no disbursement timeline has been announced [1].

The Shadow of the MDMA Rejection

Any account of the current federal push must reckon with the FDA's August 2024 decision to reject MDMA-assisted therapy for PTSD, issuing a Complete Response Letter to Lykos Therapeutics [10]. The rejection was based on specific methodological concerns: roughly 40% of study participants in the MAPP1 and MAPP2 trials had prior MDMA experience, creating selection bias; the placebo was not effectively masked; and ethical violations at one trial site involved clinical investigator misconduct [10].

The FDA publicly released the Complete Response Letter on September 4, 2025 — an unusual transparency measure [11]. The decision sent shockwaves through the psychedelic medicine field. Other developers adjusted their strategies, recruiting psychedelic-naive participants and tracking long-term efficacy data up to one year [12].

Critics of the executive order argue the political push is running ahead of the science. The FDA's independent advisory committee voted 9-2 against recommending MDMA approval in June 2024, and the underlying data concerns have not been fully addressed by new trials [10]. Supporters counter that the FDA's rejection of one specific application for one specific compound should not hold back an entire class of medicines, and that the National Priority Voucher system still requires companies to meet safety and efficacy standards [3].

The Research Boom

Academic interest in psychedelic therapy has surged over the past decade. According to OpenAlex data, published research papers on psychedelic therapy grew from 70 in 2011 to a peak of 2,158 in 2024 [13].

Source: OpenAlex

Data as of Jan 1, 2026CSV

This research boom has produced evidence across multiple compounds. Psilocybin has shown efficacy in treatment-resistant depression in Phase II trials. Ibogaine has drawn attention for its potential in treating opioid addiction. Ketamine — already FDA-approved in the form of Janssen's esketamine nasal spray Spravato, which generated $780 million in sales in the first three quarters of 2024 — has established commercial proof of concept for psychedelic-adjacent medicine [14].

Who Stands to Profit

The financial stakes are substantial. AbbVie acquired Gilgamesh Pharmaceuticals' compound bretisilocin for up to $1.2 billion, marking the first time a major pharmaceutical company purchased an investigational psychedelic drug [14]. Federal lobbying spending among psychedelic developers reached a new high in the third quarter of 2025, though Lykos Therapeutics — previously the sector's biggest lobbying spender — terminated its federal lobbying after the MDMA rejection [15].

The executive order's emphasis on public-private coordination and its directive to "reduce restrictions hampering research" have been welcomed by industry [1]. Stock prices for publicly traded psychedelic companies rose sharply following the announcement [16]. Whether administration officials or their close associates hold financial interests in psychedelic firms has not been publicly disclosed, and no financial conflict-of-interest reports specific to this policy area have been released as of this writing.

The International Scorecard

The U.S. is not the first country to move on psychedelic therapy, and international experience offers both encouragement and caution.

Australia became the first nation to approve psilocybin and MDMA for prescription use, effective July 1, 2023 [17]. The program is limited to authorized psychiatrists treating treatment-resistant depression (psilocybin) and PTSD (MDMA). Early reports suggest uptake has been slower than expected, partly due to the high cost of treatment and the limited number of authorized prescribers.

Canada has allowed compassionate access to psilocybin since 2020, and Alberta became the first province to legalize multiple psychedelic compounds for therapeutic use in 2023 [18]. Preliminary longitudinal data from Canadian patients receiving compassionate access showed psychiatric benefits consistent with clinical trial results, though one participant reported a substantial decrease in well-being — a reminder that outcomes are not uniformly positive [19].

The Netherlands' parliament recommended fast-tracking MDMA-assisted psychotherapy for PTSD in May 2025 [18]. Jamaica has long permitted legal psilocybin retreats due to the absence of domestic prohibition.

The lesson from Australia and Canada is that regulatory approval alone does not guarantee access. Without insurance coverage, trained practitioners, and infrastructure, approval can remain largely symbolic.

The Access and Equity Gap

Cost is the central barrier. Psychedelic-assisted therapy is resource-intensive, requiring multiple preparatory sessions, extended drug-administration sessions (often six to eight hours), and follow-up integration therapy — all with trained clinicians present. Research on group therapy models has shown potential savings: group MDMA-assisted therapy for PTSD saved 50.9% of clinician costs ($3,467 per patient) compared to individual treatment, and group psilocybin therapy for major depressive disorder saved 34.7% ($981 per patient) [20].

Whether insurance will cover these treatments remains uncertain. The Veterans Health Administration Novel Therapeutics Preparedness Act mandates coordination with CMS and HHS to establish reimbursement pathways, but no concrete coverage framework exists [9]. Without Medicaid reimbursement, access will be limited to those who can pay out of pocket.

The clinical trial population raises additional concerns. Non-Hispanic white participants remain significantly overrepresented in psychedelic research, while people of color and women are underrepresented both as participants and in research leadership [21]. An analysis in The Lancet's eClinicalMedicine found that 84.3% of people affected by mental illness live in low- and middle-income countries, yet psychedelic trials are concentrated in the U.S., Europe, Australia, New Zealand, and Israel [21]. The Equity in Psychedelic Therapy Initiative has called for targeted efforts to make psychedelic therapy accessible to BIPOC communities, including training a diverse workforce of social workers, counselors, and peer support specialists [22].

Medicalization vs. Decriminalization: A Fundamental Divide

Not everyone working toward psychedelic access supports the federal medicalization model. Drug-policy reformers and civil libertarians argue that routing psychedelic access exclusively through the pharmaceutical and medical system entrenches corporate gatekeeping, keeps prices high, and does nothing for the communities most harmed by drug criminalization [23].

The numbers tell a story of growing grassroots momentum alongside federal action. Twenty-five states have considered 74 psychedelic-related bills, with 10 enacted and 32 still active as of early 2026. The number of bills introduced grew from 5 in 2019 to 36 in 2022 and has remained elevated since [24].

Source: Psychedelic Alpha

Data as of Apr 25, 2026CSV

Oregon became the first state to both decriminalize psilocybin and legalize supervised non-medical use in 2020. Colorado decriminalized personal cultivation, possession, and consumption of psilocybin mushrooms, DMT, ibogaine, and mescaline for adults 21 and older, with regulated healing centers opening in 2025 [24].

The steelman case against the federal medicalization-only approach: FDA approval and pharmaceutical distribution will produce treatments costing thousands of dollars per course, accessible primarily to insured, affluent patients. Meanwhile, non-clinical use will remain criminalized under federal law, and the communities of color disproportionately arrested and incarcerated for drug offenses will see no relief from an executive order that channels access through medical institutions. As researchers at the Harvard Petrie-Flom Center have noted, the tension between pharmaceutical regulation and broader access reform remains unresolved [5].

Proponents of the medicalization path respond that FDA approval is the fastest route to insurance coverage, that clinical oversight is necessary given the documented risks of psychedelic use, and that decriminalization without medical infrastructure could expose vulnerable people to harm.

Safety Concerns and Missing Safeguards

The risks are real and documented. Psychedelic substances produce altered states of consciousness that increase patient suggestibility and vulnerability. Reports of therapist sexual misconduct during psychedelic-assisted sessions — including cases associated with underground therapy and at least one clinical trial site — have raised alarms [25].

Current safeguards in clinical trials include requiring two therapists present during sessions and mandatory video recording of therapy sessions [25]. But professional competency standards for psychedelic therapists remain undefined, and the psychotherapy component of treatment is far less regulated than the drug itself [26].

The FDA's MDMA rejection was driven in part by ethical violations at a trial site involving investigator misconduct — underscoring that existing oversight mechanisms failed to prevent problems even within a controlled research setting [10].

The executive order does not specify new safety requirements for psychedelic-assisted therapy. It directs agencies to "reduce restrictions," but does not address therapist credentialing, session monitoring standards, or protections against coercive use in institutional settings such as prisons or the military [1]. Legal scholars have raised concerns that Right to Try access, which bypasses the full FDA approval process, could reduce oversight further [5].

The question of coercive use in institutional settings — whether military commanders or prison administrators could pressure individuals into psychedelic treatment — remains unaddressed in current federal proposals.

What Comes Next

The FDA is expected to complete its National Priority Voucher reviews of the three psychedelic compounds — two psilocybin applications and one methylone application — within months rather than the typical timeline of years [3]. If any receive approval, it would mark the first time a classic psychedelic has gained full FDA authorization.

Congress continues to advance parallel legislation. The PATH Caucus's Innovative Therapies Centers of Excellence Act and the VA Novel Therapeutics Preparedness Act both await floor votes [8][9]. At the state level, New York is considering a psilocybin-assisted therapy pilot for veterans and first responders, Missouri's House passed a study bill 137-11, and Minnesota has advanced a bill to legalize psilocybin-assisted therapy [8].

The science, the politics, the money, and the ethics are all moving at different speeds. The executive order has accelerated the political timeline. Whether the clinical evidence, safety infrastructure, and access frameworks can keep pace will determine whether this moment produces lasting benefit or becomes a cautionary tale about the costs of rushing medicine to market.